Request for Comments on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights (USPTO Docket No. PTO-P-2022-0025)
Public Comment Joint USPTO-FDA Collaboration Initiatives; Notice of Public Listening Session
Supplemental Comments on the Joint USPTO-FDA Collaboration Initiatives Listening Session
Drug Patent Book
Overpatented, Overpriced 2022
The Truth About America’s Top Selling Drugs 2021
New Report: Ending Drug Patent Abuse Critical Next Step in Taming Soaring Drug Costs
Letter to Senator Tillis
ITC Adalimumab Submission
Lowering Prescription Drug Costs by Removing Barriers to Challenging Patents